Background A now extensive literature has documented political strategies of health-harming industries (HHIs), but little is known about their engagement with parliamentary select committees. Recent investments by trans-national tobacco corporations (TTCs) in electronic nicotine delivery systems (ENDS) has raised concerns that industry actors may be using these to re-engage policy-makers in ways precluded by the Framework Convention on Tobacco Control (FCTC) Article 5.3.
Methods This article examines tobacco industry engagement with the United Kingdom House of Commons Science and Technology Committee (STC) inquiry into e-cigarettes. It draws on a qualitative analysis of semi-structured interviews with committee members and support staff (n = 4) triangulated against written and oral evidence submissions.
Results TTCs featured prominently in the STC inquiry via written and oral submissions. Opportunities existed for industry engagement, and potential influence, at each stage of the process. There was an absence of oral testimony from those sceptical about the potential health benefits of ENDS. The governance mechanisms in place for select committees appear inadequate for protecting committee work from industry influence. As it relates to TTCs, this has implications for the UK’s commitments under FCTC Article 5.3, yet understanding of the FCTC and the requirements of Article 5.3 compliance within the committee were limited.
Conclusion The governance of select committees requires urgent reform in order to balance norms of openness and participation with the need to protect their work from power of economic actors with conflicts of interest (COI). This is particularly the case in relation to TTCs and adherence to FCTC Article 5.3. These findings are of relevance to other select committees whose work affects the interests of HHIs. Further research is needed on other committees and sectors.
Lacy-Nichols J, Nandi S, Mialon M, et al. Conceptualising commercial entities in public health: beyond unhealthy commodities and transnational corporations. Lancet. 2023;401(10383):1214-1228. doi:1016/s0140-6736(23)00012-0
Gilmore AB, Fabbri A, Baum F, et al. Defining and conceptualising the commercial determinants of health. Lancet. 2023;401(10383):1194-1213. doi:1016/s0140-6736(23)00013-2
Hird TR, Gallagher AWA, Evans-Reeves K, et al. Understanding the long-term policy influence strategies of the tobacco industry: two contemporary case studies. Tob Control. 2022;31(2):297-307. doi:1136/tobaccocontrol-2021-057030
Mialon M. An overview of the commercial determinants of health. Global Health. 2020;16(1):74. doi:1186/s12992-020-00607-x
Kenworthy N, MacKenzie R. Case Studies on Corporations and Global Health Governance: Impacts, Influence and Accountability. Pickering & Chatto Publishers; 2016.
Savell E, Fooks G, Gilmore AB. How does the alcohol industry attempt to influence marketing regulations? A systematic review. Addiction. 2016;111(1):18-32. doi:1111/add.13048
Smith KE, Savell E, Gilmore AB. What is known about tobacco industry efforts to influence tobacco tax? A systematic review of empirical studies. Tob Control. 2013;22(2):144-153. doi:1136/tobaccocontrol-2011-050098
Brandt AM. Inventing conflicts of interest: a history of tobacco industry tactics. Am J Public Health. 2012;102(1):63-71. doi:2105/ajph.2011.300292
McCambridge J, Mialon M. Alcohol industry involvement in science: a systematic review of the perspectives of the alcohol research community. Drug Alcohol Rev. 2018;37(5):565-579. doi:1111/dar.12826
Benton M, Russell M. Assessing the impact of parliamentary oversight committees: the select committees in the British House of Commons. Parliam Aff. 2012;66(4):772-797. doi:1093/pa/gss009
Hawkins B, Oliver K. Select committee governance and the production of evidence: the case of UK e-cigarettes policy. In: Fafard P, Cassola A, de Leeuw E, eds. Integrating Science and Politics for Public Health. Cham: Springer; 2022:187-208. doi:1007/978-3-030-98985-9_9
World Health Organization (WHO). WHO Framework Convention on Tobacco Control. 2003. https://fctc.who.int/publications/i/item/9241591013. Accessed August 13, 2024.
Chapman S. Quit Smoking Weapons of Mass Distraction. Sydney University Press; 2022.
Fairchild AL, Bayer R, Lee JS. The e-cigarette debate: what counts as evidence? Am J Public Health. 2019;109(7):1000-1006. doi:2105/ajph.2019.305107
McNeill A, Brose L, Calder R, Robson D, Bauld L, Dockrell M. E-cigarette regulation in the United States and the United Kingdom: two countries divided by a common language. Am J Public Health. 2019;109(11):e26-e27. doi:2105/ajph.2019.305346
Smith KE, Ikegwuonu T, Weishaar H, Hilton S. Evidence use in e-cigarettes debates: scientific showdowns in a 'wild west' of research. BMC Public Health. 2021;21(1):362. doi:1186/s12889-021-10396-6
Hawkins B, Ettelt S. The strategic uses of evidence in UK e-cigarettes policy debates. Evid Policy. 2019;15(4):579-596. doi:1332/174426418x15212872451438
Weishaar HB, Ikegwuonu T, Smith KE, Buckton CH, Hilton S. E-cigarettes: a disruptive technology? An analysis of health actors' positions on e-cigarette regulation in Scotland. Int J Environ Res Public Health. 2019;16(17):3103. doi:3390/ijerph16173103
Eisenkraft Klein D, Hawkins B, Schwartz R. Understanding experts’ conflicting perspectives on tobacco harm reduction and e-cigarettes: an interpretive policy analysis. SSM Qual Res Health. 2022;2:100197. doi:1016/j.ssmqr.2022.100197
Mathers A, Hawkins B, Lee K. Transnational tobacco companies and new nicotine delivery systems. Am J Public Health. 2019;109(2):227-235. doi:2105/ajph.2018.304813
Maziak W. E-cigarettes: harm reduction or rehabilitation of the tobacco industry? Int J Public Health. 2020;65(2):159-161. doi:1007/s00038-019-01316-y
Peeters S, Gilmore AB. Understanding the emergence of the tobacco industry's use of the term tobacco harm reduction in order to inform public health policy. Tob Control. 2015;24(2):182-189. doi:1136/tobaccocontrol-2013-051502
Peeters S, Gilmore AB. Transnational tobacco company interests in smokeless tobacco in Europe: analysis of internal industry documents and contemporary industry materials. PLoS Med. 2013;10(9):e1001506. doi:1371/journal.pmed.1001506
McCambridge J, Kypri K, Drummond C, Strang J. Alcohol harm reduction: corporate capture of a key concept. PLoS Med. 2014;11(12):e1001767. doi:1371/journal.pmed.1001767
McCambridge J, Mialon M, Hawkins B. Alcohol industry involvement in policymaking: a systematic review. Addiction. 2018;113(9):1571-1584. doi:1111/add.14216
Hurt RD, Ebbert JO, Muggli ME, Lockhart NJ, Robertson CR. Open doorway to truth: legacy of the Minnesota tobacco trial. Mayo Clin Proc. 2009;84(5):446-456. doi:1016/s0025-6196(11)60563-6
Apollonio DE, Bero LA. The creation of industry front groups: the tobacco industry and "get government off our back". Am J Public Health. 2007;97(3):419-427. doi:2105/ajph.2005.081117
Brandt A. The Cigarette Century: The Rise, Fall, and Deadly Persistence of the Product That Defined America. New York, NY: Basic Books; 2009.
Daube M, Moodie R, McKee M. Towards a smoke-free world? Philip Morris International's new Foundation is not credible. Lancet. 2017;390(10104):1722-1724. doi:1016/s0140-6736(17)32561-8
van der Eijk Y, Bero LA, Malone RE. Philip Morris International-funded 'Foundation for a Smoke-Free World': analysing its claims of independence. Tob Control. 2019;28(6):712-718. doi:1136/tobaccocontrol-2018-054278
Russell M, Benton M. Selective Influence: The Policy Impact of House of Commons Select Committees. London: Constitution Unit; 2011.
Russell M, Gover D. Legislation at Westminster: Parliamentary Actors and Influence in the Making of British Law. Oxford University Press; 2017.
Geddes M, Dommett K, Prosser B. A recipe for impact? Exploring knowledge requirements in the UK Parliament and beyond. Evid Policy. 2018;14(2):259-276. doi: 1332/174426417x14945838375115.
Geddes M. Dramas at Westminster. In: Dramas at Westminster. Manchester University Press; 2019:137-148. doi: 7765/9781526136817.00015.
Fooks GJ, Smith J, Lee K, Holden C. Controlling corporate influence in health policy making? An assessment of the implementation of article 5.3 of the World Health Organization framework convention on tobacco control. Global Health. 2017;13(1):12. doi:1186/s12992-017-0234-8
Assunta M. Global Tobacco Industry Interference Index 2023. Bangkok, Thailand: Global Center for Good Governance in Tobacco Control; 2023. https://globaltobaccoindex.org/report-summary.
McKee M. Evidence and E-cigarettes: explaining English exceptionalism. Am J Public Health. 2019;109(7):965-966. doi:2105/ajph.2019.305132
Geddes M. Committee hearings of the UK Parliament: who gives evidence and does this matter? Parliam Aff. 2017;71(2):283-304. doi:1093/pa/gsx026
Lukes S. Power: A Radical View. London: Macmillan; 1974.
Campus B, Fafard P, St Pierre J, Hoffman SJ. Comparing the regulation and incentivization of e-cigarettes across 97 countries. Soc Sci Med. 2021;291:114187. doi:1016/j.socscimed.2021.114187
Hawkins B, Holden C. ‘Water dripping on stone’? Industry lobbying and UK alcohol policy. Policy Polit. 2014;42(1):55-70. doi:1332/030557312x655468
Hawkins, B. (2024). Tobacco Industry Engagement in the House of Commons Science and Technology Select Committee E-Cigarettes Inquiry. International Journal of Health Policy and Management, 13(1), 1-10. doi: 10.34172/ijhpm.8341
MLA
Benjamin Hawkins. "Tobacco Industry Engagement in the House of Commons Science and Technology Select Committee E-Cigarettes Inquiry", International Journal of Health Policy and Management, 13, 1, 2024, 1-10. doi: 10.34172/ijhpm.8341
HARVARD
Hawkins, B. (2024). 'Tobacco Industry Engagement in the House of Commons Science and Technology Select Committee E-Cigarettes Inquiry', International Journal of Health Policy and Management, 13(1), pp. 1-10. doi: 10.34172/ijhpm.8341
VANCOUVER
Hawkins, B. Tobacco Industry Engagement in the House of Commons Science and Technology Select Committee E-Cigarettes Inquiry. International Journal of Health Policy and Management, 2024; 13(1): 1-10. doi: 10.34172/ijhpm.8341